S 3738
115th Congress
Senate
Health
Administrative remedies
Drug safety, medical device, and laboratory regulation
Fraud offenses and financial crimes
Intellectual property
Licensing and registrations
Prescription drugs
Securities
Hatch-Waxman Integrity Act of 2018
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 11, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Dec 11, 2018
Introduced in Senate
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Hatch-Waxman Integrity Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.
What's happening now
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related & companion bills
1
Bill text
1 version
- Introduced in Senate Formatted Text PDF Formatted XML
Committees of jurisdiction
1
Cosponsors
1
Cite this page
U.S. Congress. (2026). S. 3738: Hatch-Waxman Integrity Act of 2018. 115th Congress. Open America. https://openamerica.io/bill/115-S-3738/
"S. 3738: Hatch-Waxman Integrity Act of 2018." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-3738/.
S. 3738, 115th Cong. (2026), https://openamerica.io/bill/115-S-3738/.
[S. 3738: Hatch-Waxman Integrity Act of 2018](https://openamerica.io/bill/115-S-3738/)